title: [Analysis of the changes of serum high mobility group protein B1 and cytokines in first-episode schizophrenia patients].
abstract: OBJECTIVE
  To measure serum levels of high mobility group protein B-1 (HMGB1), interleukin-1β (IL-1β), interleukin-6 (IL-6) and tumor necrosis factor-α ( TNF-α) before and after antipsychotic treatment, and further study the role of HMGB1 in schizophrenics.
  
  
  METHODS
  Thirty first-episode schizophrenics who were never treated with neuroleptics from First Affiliated Hospital of Zhengzhou University and thirty healthy subjects were enrolled. Serum levels of cytokines such as HMGB1, IL-1β, IL-6 and TNF-α were examined with enzyme linked immunosorbent assay (ELISA) before and after antipsychotic treatment.
  
  
  RESULTS
  The serum levels of HMGB1, IL-10, IL-6 and TNF-α in schizophrenics [(80 zophμ8/L, (51 zo, 441 zo, 591 zopng/L] were significantly higher than those in the healthy subjects [(54 gni) μ4/L, (25 gni, 17 gn, 41 gni) ng/L] (P < 0.05). After treating the schizophrenics with the neuroleptic risperidone for 6 months, the serum levels of HMGB1, IL-1β, TNF-α and IL-6 were decreased. The serum levels of HMGB1 were positively correlated to IL-1β, IL-6, TNF-α and Negative Symptoms (r = 0.377, r = 0.426, r = 0.454, r = 0.558, P < 0.05).
  
  
  CONCLUSIONS
  Schizophrenics show activation of the cytokine system and immune disturbance. HMGB1 may play a proinflammatory role in schizophrenia and the decrease of HMGB1 after neuroleptic risperidone treatment may be a marker of mental symptoms remission.
authors.forename: Qiyu
authors.initials: Q
authors.lastname: Zhu
authors.forename: Xue
authors.initials: X
authors.lastname: Li
authors.forename: Gangrui
authors.initials: G
authors.lastname: Hie
authors.forename: Xiuxia
authors.initials: X
authors.lastname: Yuan
authors.forename: Luxian
authors.initials: L
authors.lastname: Lü
authors.forename: Xueqin
authors.initials: X
authors.lastname: Song
mesh_terms: D014150:Antipsychotic Agents / Q000627:therapeutic use; D015415:Biomarkers / Q000097:blood; D016022:Case-Control Studies; D016207:Cytokines / Q000097:blood*; D004797:Enzyme-Linked Immunosorbent Assay; D024243:HMGB1 Protein / Q000097:blood*; D006801:Humans; D016753:Interleukin-10 / Q000097:blood; D053583:Interleukin-1beta / Q000097:blood; D015850:Interleukin-6 / Q000097:blood; D018967:Risperidone / Q000627:therapeutic use; D012559:Schizophrenia / Q000097:blood* / Q000188:drug therapy*; D014409:Tumor Necrosis Factor-alpha / Q000097:blood
chemical_list: D014150:Antipsychotic Agents; D015415:Biomarkers; D016207:Cytokines; D024243:HMGB1 Protein; C585491:HMGB1 protein, human; C508609:IL10 protein, human; C508585:IL1B protein, human; C508600:IL6 protein, human; D053583:Interleukin-1beta; D015850:Interleukin-6; D014409:Tumor Necrosis Factor-alpha; D016753:Interleukin-10; D018967:Risperidone